Lockheed Martin Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Lockheed Martin Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,500	Closed	-$279K	–	133
2018 Q1	$279K	Buy	2,500 +500	+25%	+$59.8K	0.01%	122
2017 Q4	$239K	Sell	2,000 -6,000	-75%	-$731K	0.01%	124
2017 Q3	$1.12M	Sell	8,000 -9,200	-53%	-$1.25M	0.06%	99
2017 Q2	$2.09M	Buy	17,200 +7,000	+69%	+$815K	0.11%	85
2017 Q1	$1.24M	Sell	10,200 -10,000	-50%	-$1.29M	0.07%	104
2016 Q4	$2.47M	Sell	20,200 -9,400	-32%	-$1.15M	0.21%	57
2016 Q3	$3.63M	Buy	29,600 +9,600	+48%	+$1.24M	0.31%	46
2016 Q2	$2.33M	Buy	+20,000	New	+$2.84M	0.23%	63
2015 Q4	–	Sell	-6,500	Closed	-$1.02M	–	106
2015 Q3	$1.02M	Sell	6,500 -19,000	-75%	-$3.47M	0.11%	65
2015 Q2	$4.61M	Sell	25,500 -9,200	-27%	-$1.59M	0.23%	49
2015 Q1	$6.01M	Buy	34,700 +20,700	+148%	+$3.75M	0.29%	41
2014 Q4	$2.59M	Sell	14,000 -2,000	-13%	-$371K	0.11%	56
2014 Q3	$2.65M	Buy	+16,000	New	+$2.63M	0.12%	63

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lockheed Martin Investment Management's ALXN Position: Q2 2018 in Review

Lockheed Martin Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 2,500 shares — an estimated $279K sold.

Lockheed Martin Investment Management first reported a position in ALXN in Q3 2014 and held it in 13 quarters. The position peaked at $6.01M in Q1 2015. 600 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

Lockheed Martin Investment Management reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Lockheed Martin Investment Management sold 2,500 Alexion Pharmaceuticals shares in Q2 2018, an estimated $279K.
Lockheed Martin Investment Management first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 13 quarters.
Lockheed Martin Investment Management's Alexion Pharmaceuticals position peaked at $6.01M in Q1 2015.
600 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Lockheed Martin Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.